Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - Australian Red Cross Blood Service - Blood Donor Centre Traralgon West

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, addresses the regulation and control of therapeutic goods within the country. This Act establishes a comprehensive framework to ensure that therapeutic goods available in Australia meet safety, quality, and efficacy standards. One of its key objectives is to maintain and enhance public health by regulating the manufacture, supply, and advertising of therapeutic goods, ensuring they are safe for use by consumers. The revocation of a licence to manufacture therapeutic goods, as detailed in this gazette, highlights the Act's role in maintaining regulatory oversight and ensuring compliance with established standards, thereby protecting public health and safety. The revocation of a manufacturer's licence under this Act is a measure taken to uphold these objectives and maintain the integrity of the therapeutic goods market.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, supply, importation, and distribution of therapeutic goods within Australia. This includes both the entities themselves, such as pharmaceutical companies and medical device manufacturers, and the individuals who manage or operate these entities. The Act covers the entire Commonwealth of Australia, with its provisions applying uniformly across all states and territories. The Act mandates licensing for the manufacture of therapeutic goods and provides the legal framework for the regulation of these goods to ensure they meet safety, quality, and efficacy standards. However, the Act also delineates certain exclusions, such as specific goods exempt from its licensing requirements, and may allow for exemptions or thresholds in certain circumstances as specified in the legislation or subordinate instruments. Subordinate instruments may further extend or restrict the application of the Act by specifying additional conditions, requirements, or exemptions relevant to particular types of therapeutic goods or manufacturing processes.

Key Provisions

The Therapeutic Goods Act 1989, under section 41(1)(d), provides the Secretary with the authority to revoke a licence for the manufacture of therapeutic goods. This section has been exercised in the case of the Australian Red Cross Blood Service, an operating division of the Australian Red Cross Society, specifically for their Blood Donor Centre in Traralgon West. The relevant licence number, MI-17082005-LI-000796-1, pertains to the La Trobe Regional Hospital Consulting Suite at 5 Princes Highway, Traralgon West, VIC 3844. The revocation occurred at the request of the manufacturer and was published in Gazette C2013G00384 on 5 February 2013, signed by Bill Turner, who acted as the delegate of the Secretary. The obligations and requirements imposed by the Therapeutic Goods Act 1989 on entities like the Australian Red Cross Blood Service include ensuring compliance with all regulatory standards set forth by the Therapeutic Goods Administration (TGA). This encompasses the manufacturing processes, quality control measures, and adherence to safety and efficacy standards. Any entity that holds a licence to manufacture therapeutic goods must regularly submit reports and data to the TGA, demonstrating their compliance with these standards. Furthermore, the Act mandates that manufacturers must maintain proper records and documentation, which can be audited by the TGA at any time to ensure ongoing compliance. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in significant consequences. For instance, revocation of a manufacturing licence, as seen in the case of the Australian Red Cross Blood Service, is a direct outcome of non-compliance or other regulatory breaches. Additionally, the Act outlines various offences that can lead to civil or criminal penalties. For example, knowingly manufacturing or supplying a therapeutic good that does not meet the required standards could result in substantial fines, with the maximum penalty often tied to the severity and intent behind the breach. In criminal cases, individuals responsible for the breach could face imprisonment, further highlighting the seriousness with which the Act treats non-compliance.